Abstract
A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.
| Original language | Italian |
|---|---|
| Pages (from-to) | 626-650 |
| Number of pages | 25 |
| Journal | Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali |
| Volume | 115 |
| Issue number | 4 |
| Publication status | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
PROFILO GENERALE DELLA FLUVOXAMINA. / De Maio, D.; Bertolino, A.; Casacchia, M.; Ceccarelli, G.; Ecari, U.; Giove, C.; Marino, A.; Rizzoli, A. A.; Savoldi, F.
In: Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali, Vol. 115, No. 4, 1991, p. 626-650.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PROFILO GENERALE DELLA FLUVOXAMINA
AU - De Maio, D.
AU - Bertolino, A.
AU - Casacchia, M.
AU - Ceccarelli, G.
AU - Ecari, U.
AU - Giove, C.
AU - Marino, A.
AU - Rizzoli, A. A.
AU - Savoldi, F.
PY - 1991
Y1 - 1991
N2 - A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.
AB - A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.
UR - http://www.scopus.com/inward/record.url?scp=0025999996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025999996&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0025999996
VL - 115
SP - 626
EP - 650
JO - Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali
JF - Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali
SN - 0035-7057
IS - 4
ER -